New Patent Grant for GeneICE & VAL101 Update
This follows the previously announced grant of patents for the technology across the world encompassing territories including the US, Europe and Australia.
ValiRx’s GeneICE technology has been developed for silencing rebellious genes, which cause conditions such as cancer and various neurological problems.
Imperial College, University of London, from whom the technology was originally licensed, has been working in collaboration with ValiRx and is currently carrying out the late preclinical development of ValiRx’s lead therapeutic, VAL101 with funding awarded from the prestigious Eurostars scheme.
Results from the preclinical programme have shown efficacy in killing cancer cells in several systems, as the Company has reported previously, and ValiRx is delighted to announce that its agreement with Imperial College has now been extended and that Imperial College will continue with further development of this cancer therapeutic work. Stability and toxicology studies are currently underway. The production of the VAL101 compound is going to plan and has been optimised and simplified, which by extension makes the compound cheaper to produce, thereby adding future value.
ValiRx is also pleased to report that the previously announced extension to its Eurostars grant for the development of its GeneICE technology, is extending the Company’s pipeline of potential cancer therapeutic compounds, with VAL101 progressing well in preclinical development.
Dr Satu Vainikka, CEO, commented: “I am very pleased with the progress we are seeing regarding VAL101 and our GeneICE drug candidates and the invaluable support we are receiving both from Imperial College and from Eurostars. The filing of this latest patent extends our global geographic patent coverage and I believe it represents a value marker for the Company, as we further progress the GeneICE preclinical programme.